Lanreotide depot/autogel (LAN) in pancreatic neuroendocrine tumors (pNETs): A subgroup analysis from the CLARINET study.

被引：0
|
作者：
Phan, Alexandria T.
Caplin, Martyn E.
Pavel, Marianne E.
Cwikla, Jaroslaw B.
Raderer, Markus
Sedlackova, Eva
Cadiot, Guillaume
Wolin, Edward M.
Capdevila, Jaume
Wall, Lucy
Rindi, Guido
Langley, Alison
Gomez-Panzani, Edda
Ruszniewski, Philippe B.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Royal Free Hosp, London NW3 2QG, England
[3] Charite, D-13353 Berlin, Germany
[4] Univ Varmia & Masuria, Olsztyn, Poland
[5] Univ Hosp Vienna, Vienna, Austria
[6] Fac Med 1, Prague, Czech Republic
[7] Gen Teaching Hosp, Prague, Czech Republic
[8] Hop Robert Debre, Reims, France
[9] Univ Kentucky, Lexington, KY USA
[10] VHIO, Barcelona, Spain
[11] Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland
[12] Univ Cattolica Sacro Cuore, Rome, Italy
[13] Ipsen, Les Ulis, France
[14] Hop Beaujon, Clichy La Garenne, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e15178
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15178
引用
收藏
页数：1
相关论文
共 50 条
  • [41] CLARINET FORTE Baseline Characteristics: Lanreotide Autogel 120 mg (LAN) Every 14 Days in Patients With Progressive Pancreatic or Midgut Neuroendocrine Tumors During a Standard First-Line LAN Regimen
    Ruszniewski, Philippe
    Cwikla, Jaroslaw
    Lombard-Bohas, Catherine
    Borbath, Ivan
    Shah, Tahir
    Pape, Ulrich -Frank
    Xuan-Mai Truong Thanh
    Houchard, Aude
    Pavel, Marianne
    PANCREAS, 2020, 49 (03) : 484 - 485
  • [42] Lanreotide autogel/depot (LAN) treatment for carcinoid syndrome (CS) symptoms: Patient-reported outcomes (PROs) from the SYMNET study.
    Ruszniewski, Philippe B.
    Caplin, Martyn E.
    Valle, Juan W.
    Lombard-Bohas, Catherine
    Poston, Graeme John
    Perros, Petros
    Holubec, Lubos
    Delle Fave, Gianfranco
    Smith, Denis Michel
    Niccoli, Patricia
    Maisonobe, Pascal
    Atlan, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] Long-term safety/tolerability of lanreotide autogel/depot (LAN) treatment for metastatic intestinal and pancreatic neuroendocrine tumours (NETs): Final results of the CLARINET open-label extension (OLE)
    Caplin, M.
    Pavel, M.
    Cwikla, J. C.
    Phan, A.
    Raderer, M.
    Sedlackova, E.
    Cadiot, G.
    Wolin, E.
    Capdevila, J.
    Wall, L.
    Rindi, G.
    Liyanage, N.
    Braun, S.
    Ruszniewski, P.
    ANNALS OF ONCOLOGY, 2016, 27
  • [44] Tumor Growth Rate (TGR) as an Indicator of Antitumor Activity With Lanreotide Autogel/Depot (LAN) Versus Placebo (Pbo) in Intestinal/Pancreatic NET: Post Hoc Analysis of CLARINET Data
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (05) : 6 - 7
  • [45] SPINET: A Randomized, Double-blind, Placebo-controlled Phase III Study of Lanreotide Autogel/Depot (LAN) in Patients with Advanced Lung Neuroendocrine Tumors
    Reidy-Lagunes, Diane
    Kulke, Matthew
    Wolin, Edward
    Singh, Simron
    Ferone, Diego
    Mirakhur, Beloo
    Hoffmanns, Philipp
    Houchard, Aude
    Caplin, Martyn
    Baudin, Eric
    PANCREAS, 2017, 46 (03) : 451 - 451
  • [46] Tumor Growth Rate (TGR) as an Indicator of Antitumor Activity with Lanreotide Autogel/Depot (LAN) vs. Placebo (Pbo) in Intestinal/Pancreatic NET: Post Hoc Analysis of CLARINET Data
    Caplin, M.
    Pavel, M.
    Ruszniewski, P.
    Liyanage, N.
    Massien, C.
    Dromain, C.
    NEUROENDOCRINOLOGY, 2016, 103 : 73 - 73
  • [47] Lanreotide Depot/Autogel Before, During, and After Peptide Receptor Radionuclide Therapy in Advanced Neuroendocrine Tumors: Data from the PRELUDE Study (*)
    Prasad, Vikas
    Srirajaskanthan, Raj
    Toumpanakis, Christos
    Grana, Chiara M.
    Baldari, Sergio
    Shah, Tahir
    Lamarca, Angela
    Courbon, Frederic
    Scheidhauer, Klemens
    Baudin, Eric
    Xuan-Mai Truong Thanh
    Houchard, Aude
    Bodei, Lisa
    PANCREAS, 2019, 48 (03) : 448 - 449
  • [48] Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/ Depot (LAN) for Patients with Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: The Prospective, Open-label, International, Phase 2 CLARINET FORTE Study
    Pavel, M.
    Dromain, C.
    Majdi, A.
    Houchard, A.
    NEUROENDOCRINOLOGY, 2017, 105 : 204 - 204
  • [49] Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/Depot (LAN) for Pts with Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: Prospective, Open-label, International, Phase 2 CLARINET FORTE Study
    Pavel, M.
    Dromain, C.
    Thanh, Truong X. M.
    Houchard, A.
    NEUROENDOCRINOLOGY, 2019, 108 : 157 - 157
  • [50] Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study
    Pavel, Marianne
    Lahner, Harald
    Hoersch, Dieter
    Rinke, Anja
    Denecke, Timm
    Koch, Arend
    Regnault, Benjamin
    Helbig, Dorit
    Hoffmanns, Philipp
    Raderer, Markus
    ONCOLOGIST, 2024, : e643 - e654
12345